0001209191-22-028889.txt : 20220513
0001209191-22-028889.hdr.sgml : 20220513
20220513163735
ACCESSION NUMBER: 0001209191-22-028889
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220511
FILED AS OF DATE: 20220513
DATE AS OF CHANGE: 20220513
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lachey Jennifer
CENTRAL INDEX KEY: 0001808322
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39264
FILM NUMBER: 22923410
MAIL ADDRESS:
STREET 1: C/O KEROS THERAPEUTICS, INC.
STREET 2: 99 HAYDEN AVENUE, SUITE 120, BUILDING E
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Keros Therapeutics, Inc.
CENTRAL INDEX KEY: 0001664710
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E)
STREET 2: LEDGEMONT TECHNOLOGY CENTER
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-513-8774
MAIL ADDRESS:
STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E)
STREET 2: LEDGEMONT TECHNOLOGY CENTER
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-05-11
0
0001664710
Keros Therapeutics, Inc.
KROS
0001808322
Lachey Jennifer
C/O KEROS THERAPEUTICS, INC.
99 HAYDEN AVENUE, SUITE 120, BUILDING E
LEXINGTON
MA
02421
0
1
0
0
Chief Scientific Officer
Common Stock
2022-05-11
4
M
0
5300
0.30
A
91000
D
Common Stock
2022-05-11
4
S
0
3398
41.26
D
87602
D
Common Stock
2022-05-11
4
S
0
944
42.49
D
86658
D
Common Stock
2022-05-11
4
S
0
719
43.32
D
85939
D
Common Stock
2022-05-11
4
S
0
223
44.23
D
85716
D
Common Stock
2022-05-11
4
S
0
16
45.45
D
85700
D
Employee Stock Option (right to buy)
0.30
2022-05-11
4
M
0
5300
0.00
D
2028-03-25
Common Stock
5300
66105
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.915 to $41.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.915 to $42.90 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $43.62 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.075 to $44.43 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.31 to $45.46 inclusive.
Immediately exercisable.
/s/ Keith Regnante, Attorney-in-Fact
2022-05-13